These findings highlight the critical role of TLR2 and TLR4 in mediating the therapeutic effects of miR-146a and anti-RANKL antibodies, underscoring the potential of TLR-targeted immunotherapy strategies for treating peri-implantitis. This evidence concerns the gene TNFSF11 and Peri-Implantitis.